IL199383A - Converted acetophenones used as 4pde inhibitors - Google Patents

Converted acetophenones used as 4pde inhibitors

Info

Publication number
IL199383A
IL199383A IL199383A IL19938309A IL199383A IL 199383 A IL199383 A IL 199383A IL 199383 A IL199383 A IL 199383A IL 19938309 A IL19938309 A IL 19938309A IL 199383 A IL199383 A IL 199383A
Authority
IL
Israel
Prior art keywords
represent
independently
pde4 inhibitors
haloalkyl
hydroxyalkyl
Prior art date
Application number
IL199383A
Other languages
English (en)
Hebrew (he)
Original Assignee
Leo Pharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leo Pharma As filed Critical Leo Pharma As
Publication of IL199383A publication Critical patent/IL199383A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61Halogen atoms or nitro radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/08Antiseborrheics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/10Anti-acne agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/14Drugs for dermatological disorders for baldness or alopecia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/16Emollients or protectives, e.g. against radiation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IL199383A 2006-12-22 2009-06-16 Converted acetophenones used as 4pde inhibitors IL199383A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US87168906P 2006-12-22 2006-12-22
US94547007P 2007-06-21 2007-06-21
PCT/DK2007/000564 WO2008077404A1 (en) 2006-12-22 2007-12-21 Substituted acetophenones useful as pde4 inhibitors

Publications (1)

Publication Number Publication Date
IL199383A true IL199383A (en) 2015-02-26

Family

ID=39156588

Family Applications (1)

Application Number Title Priority Date Filing Date
IL199383A IL199383A (en) 2006-12-22 2009-06-16 Converted acetophenones used as 4pde inhibitors

Country Status (23)

Country Link
US (3) US8148537B2 (enExample)
EP (1) EP2125736B1 (enExample)
JP (1) JP5342451B2 (enExample)
KR (1) KR101507717B1 (enExample)
AT (1) ATE503742T1 (enExample)
AU (1) AU2007336538B2 (enExample)
BR (1) BRPI0721113A2 (enExample)
CA (1) CA2673370C (enExample)
CR (1) CR10877A (enExample)
CY (1) CY1111596T1 (enExample)
DE (1) DE602007013617D1 (enExample)
DK (1) DK2125736T3 (enExample)
GT (1) GT200900172A (enExample)
HR (1) HRP20110464T1 (enExample)
IL (1) IL199383A (enExample)
MX (1) MX2009006593A (enExample)
MY (1) MY146022A (enExample)
NO (1) NO20092372L (enExample)
NZ (1) NZ577863A (enExample)
PL (1) PL2125736T3 (enExample)
PT (1) PT2125736E (enExample)
RU (1) RU2493149C2 (enExample)
WO (1) WO2008077404A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2785253A1 (en) 2009-12-22 2011-06-30 Leo Pharma A/S Calcipotriol monohydrate nanocrystals
EP2515866B1 (en) 2009-12-22 2014-02-19 Leo Pharma A/S Pharmaceutical composition comprising solvent mixture and a vitamin d derivative or analogue
JP5873439B2 (ja) 2009-12-22 2016-03-01 レオ ファーマ アクティーゼルスカブ ビタミンd類似体および溶媒と界面活性剤の混合物を含む皮膚組成物
CN102775345A (zh) * 2011-05-13 2012-11-14 上海特化医药科技有限公司 制备罗氟司特的方法及中间体
EP2925364A1 (en) * 2012-11-30 2015-10-07 Leo Pharma A/S A method of inhibiting the expression of il-22 in activated t-cells
WO2014096018A1 (en) * 2012-12-19 2014-06-26 Leo Pharma A/S Methods for the preparation of substituted acetophenones
SI3587400T1 (sl) 2013-10-22 2024-05-31 Chiesi Farmaceutici S.P.A. Postopek za pripravo zaviralca pde4
CN106459081B (zh) 2014-06-23 2019-09-10 利奥制药有限公司 1,3-苯并二氧杂环戊烯杂环化合物的制备方法
WO2017089347A1 (en) 2015-11-25 2017-06-01 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and pharmaceutical compositions for the treatment of braf inhibitor resistant melanomas
MX385592B (es) 2015-12-18 2025-03-18 Union Therapeutics As Metodos para preparacion de compuestos heterociclicos de 1,3-benzodioxol.
KR101702648B1 (ko) * 2016-05-10 2017-02-03 주식회사 엑티브온 피부 외용제용 보존제, 이를 포함하는 화장료 조성물 및 약학 조성물
CN118344381A (zh) 2017-06-20 2024-07-16 联合疗法公司 用于制备1,3-苯并二氧杂环戊烯杂环化合物的方法
EP3838967A1 (en) 2019-12-16 2021-06-23 Spago Nanomedical AB Immobilization of phenolic compounds
CN117924243B (zh) * 2024-01-16 2025-09-12 沈阳药科大学 一种喹啉衍生物及其药用组合物和应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW263495B (enExample) * 1992-12-23 1995-11-21 Celltech Ltd
GB9401460D0 (en) * 1994-01-26 1994-03-23 Rhone Poulenc Rorer Ltd Compositions of matter
JP4172817B2 (ja) * 1995-05-19 2008-10-29 協和醗酵工業株式会社 含酸素複素環化合物
US6514996B2 (en) * 1995-05-19 2003-02-04 Kyowa Hakko Kogyo Co., Ltd. Derivatives of benzofuran or benzodioxole
WO1998022455A1 (en) * 1996-11-19 1998-05-28 Kyowa Hakko Kogyo Co., Ltd. Oxygenic heterocyclic compounds
HRP20050905A2 (hr) * 2003-03-17 2006-04-30 Kyowa Hakko Kogyo Co. Terapeutski i/ili preventivni agensi za kronične kožne bolesti
WO2006040645A1 (en) * 2004-10-11 2006-04-20 Ranbaxy Laboratories Limited N-(3,5-dichloropyridin-4-yl)-2,4,5-alkoxy and 2,3,4-alkoxy benzamide derivatives as pde-iv (phophodiesterase type-iv) inhibitors for the treatment of inflammatory diseases such as asthma
EP1888528A2 (en) * 2005-06-10 2008-02-20 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors

Also Published As

Publication number Publication date
US8324394B2 (en) 2012-12-04
DE602007013617D1 (de) 2011-05-12
WO2008077404A1 (en) 2008-07-03
AU2007336538A1 (en) 2008-07-03
US20120165539A1 (en) 2012-06-28
GT200900172A (es) 2011-10-05
KR101507717B1 (ko) 2015-04-08
PL2125736T3 (pl) 2011-09-30
BRPI0721113A2 (pt) 2014-10-07
JP2010513334A (ja) 2010-04-30
RU2493149C2 (ru) 2013-09-20
PT2125736E (pt) 2011-07-01
NZ577863A (en) 2012-04-27
HK1135392A1 (en) 2010-06-04
CY1111596T1 (el) 2015-10-07
US20100035908A1 (en) 2010-02-11
CA2673370A1 (en) 2008-07-03
JP5342451B2 (ja) 2013-11-13
EP2125736A1 (en) 2009-12-02
US8148537B2 (en) 2012-04-03
US8497380B2 (en) 2013-07-30
NO20092372L (no) 2009-07-14
HRP20110464T1 (hr) 2011-07-31
EP2125736B1 (en) 2011-03-30
CA2673370C (en) 2015-11-17
MX2009006593A (es) 2009-07-02
AU2007336538B2 (en) 2012-04-05
DK2125736T3 (da) 2011-07-11
CR10877A (es) 2009-07-10
RU2009128191A (ru) 2011-01-27
KR20090098990A (ko) 2009-09-18
US20130012716A1 (en) 2013-01-10
MY146022A (en) 2012-06-15
ATE503742T1 (de) 2011-04-15

Similar Documents

Publication Publication Date Title
IL199383A (en) Converted acetophenones used as 4pde inhibitors
NO20063129L (no) Substituerte 6-cykloheksylalkylsubstituerte 2-kinolinoner og 2-kinoksalinoner som poly(ADP-ribose) polymeraseinhibitorer
NO20062892L (no) 7-fenylalkyl-substituert 2-kinolinoner og 2-kinoksalinoner som poly(adp-ribose)-polymeraseinhibitorer
UA115666C2 (uk) Заміщена оксимом амідна сполука і засіб для боротьби зі шкідниками
MX2009005449A (es) Compuesto heteromonociclico y uso del mismo.
MX2009005217A (es) Compuestos heterociclicos que contienen nitrogeno y metodos de uso de los mismos.
MY141255A (en) Phosphodiesterase 4 inhibitors, including n-substituted diarylamine analogs
WO2004004657A3 (en) Hiv integrase inhibitors
WO2007071632A3 (en) 2-pyridin-2-yl-quinazoline derivatives as potassium channel modulating agents for the treatment of respiratory diseases
EA200870321A1 (ru) Способ получения 4-оксохинолинового соединения
ZA200810739B (en) Pesticide containing novel pyridyl-methanamine derivative or its salt
NO20076145L (no) Ureadeviater, fremgangsmater for deres fremstilling og anvendelse derav
SI1742642T1 (sl) Fosfonatni analogi inhibitorskih spojin HIV integraze
TW200700422A (en) Compounds for inhibiting ksp kinesin activity
MY136824A (en) Substituted benzoxazinones and uses thereof
TW200700066A (en) Compounds for inhibiting ksp kinesin activity
UA96783C2 (ru) Замещенные метилфенилкетоны, пригодные для использования как ингибиторы pde4
ZA200500436B (en) 6-amino-1H-indazole and 4-aminobenzofuran compounds as phosphodiesterase 4 inhibitors
TW200716571A (en) Heterocyclic reverse transcriptase inhibitors
TW200719894A (en) 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydroquinoline derivatives
WO2007149211B1 (en) Dihydroorotate dehydrogenase inhibitors with selective anti-malarial activity
TW200735779A (en) Pesticidal mixtures
TW200612944A (en) 4-(2,4-dichloro-5-methoxyphenyl)amino-6-methoxy-7-{[5-(substituted-amino)methyl]-3-furyl}-3-quinolinecarbonitriles as kinase inhibitors
TW200740757A (en) Carboxamide compound and use of the same
TW200503733A (en) T-shaped channel blockers

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed